AIDS Vaccine Efficacy May Not Transfer To U.S. Population, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Army is conducting a Phase III study in Thailand of a product that combines Sanofi-Aventis and VaxGen vaccines, briefing materials for Vaccines & Related Biological Products Advisory Committee’s Sept. 23 meeting state. However, FDA considers the trial to be a “proof of concept” study.
You may also be interested in...
AIDS Vaccine's Low Efficacy Rate Makes Cmte. Skeptical About Phase III Potential
FDA committee members express concern over vaccine's low CD8 cytotoxic T lymphocyte activity and lack of neutralizing antibody response in Phase II trial. Agency cites regulatory challenge associated with approving a vaccine that is not effective against U.S. sub-type of AIDS virus.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.